New Denton facility to boost next-generation cancer treatment access across the Southern United States by 2028
Basel, Switzerland / Denton, Texas, 3 March 2026 – Global medicines company Novartis has announced plans to build a new radioligand therapy manufacturing site in Denton, Texas, strengthening its growing footprint in advanced cancer treatment. The 46,000-square-foot facility is expected to become operational in 2028 and will serve patients across the Southern United States.
This marks the company’s fifth radioligand therapy site in the U.S. and its first manufacturing facility in Texas. The investment is part of Novartis’ broader 23 billion dollar commitment to expanding its U.S. operations, focusing on biotechnology innovation, advanced manufacturing, and research and development.
Radioligand therapy, often called RLT, is an emerging form of targeted cancer treatment. In simple terms, it combines a targeting molecule with a small amount of radioactive material. The therapy is designed to attach directly to cancer cells and deliver radiation precisely where it is needed, helping to limit damage to healthy tissue. Many experts see RLT as one of the most promising advances in oncology innovation and precision medicine.
The Denton facility will play a key role as RLT expands into earlier treatment stages and additional tumor types. Novartis is currently studying radioligand therapies in several cancers, including prostate, breast, colon, lung, brain, and pancreatic cancers. As clinical trials grow and demand increases, manufacturing capacity becomes critical because each dose of RLT is custom-made and highly time-sensitive.
The company says its existing RLT network in the United States has a strong track record, with more than 99 percent of doses delivered and administered on the planned day. Because radioligand therapies must be used quickly after production, proximity to hospitals and cancer treatment centers is essential. The new Texas site will help improve supply chain efficiency and ensure faster delivery of next-generation cancer therapies across the region.
Construction of the Denton site is scheduled to begin this year. Once operational, it is expected to create new jobs in bioengineering, quality control, advanced manufacturing, and operations. This expansion reflects the growing importance of biopharmaceutical manufacturing in the United States and highlights Texas as an emerging biotech hub.
In the past ten months, Novartis has moved rapidly to strengthen its U.S. footprint. The company has broken ground on four new manufacturing and R&D facilities, initiated three expansions, and announced two additional sites. The Texas facility will join existing RLT manufacturing locations in New Jersey, Indiana, and California, as well as a newly announced site in Florida, creating a coast-to-coast radiopharmaceutical production network.
With cancer rates rising globally and demand for innovative treatments increasing, investments in advanced oncology manufacturing and targeted radiation therapy are becoming central to the future of healthcare. Through its continued expansion in radioligand therapy, Novartis aims to improve access to precision cancer treatment while building a stronger, more resilient pharmaceutical supply chain in the United States.
As the field of nuclear medicine, biotech innovation, and personalized cancer care continues to evolve, the new Denton facility represents another step toward delivering cutting-edge therapies to patients who need them most.
